SK Biopharmaceuticals (KRX:326030) posted a 158% year-over-year jump in net income attributable to owners of the parent to 85.1 billion won from 32.9 billion won for the second quarter.
Sales rose 40% to 247.4 billion won from 176.3 billion won for the three months ended June 30.
Shares of the pharmaceutical company rose 5% in recent trade.